Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Lots has happened this past week in the tech world! With artificial intelligence being called a leader in the tech market in ...

Hims & Hers Health Inc (HIMS) stock saw a modest uptick, ending the day at $28.15 which represents a slight increase of $0.55 or 1.99% from the prior close of $27.6. The stock opened at $27.97 and ...

Delving into the details, we found 11% of traders were bullish, while 66% showed bearish tendencies. Out of all the trades we ...

Buy HIMS near 25.88 target 32.47 stop loss @ 25.81 Details The technical summary data tells us to buy HIMS near 25.88 with an ...

The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved ...

It’s been nearly five years since the coronavirus broke out in the U.S., but digital health companies are still reeling.

The Short discusses a 15% drop in Hims & Hers stock following an FDA announcement ending the shortage of Eli Lilly's weight ...

Tirzepatide, the main ingredient in Mounjaro and Zepbound, is no longer in shortage, according to the U.S. Food and Drug ...

Hims recaps the year's most surprising health findings, from the growing number of adults who consider monogamy optional to ...

Craig Hettenbach, an analyst from Morgan Stanley, maintained the Buy rating on Hims & Hers Health (HIMS – Research Report). The associated ...

Hims & Hers is transforming telehealth with personalized medications, rapid subscription growth, and strong financials, ...